"Hims & Hers unveiled a once-a-day weight-loss pill this week, calling it an alternative for needle-averse customers and those looking for smaller doses. It was essentially a cheaper copy of the Wegovy pill that the pharmaceutical company, Novo Nordisk, released earlier this year. About 48 hours later, the telehealth company said it would stop selling it. "Since launching the compounded semaglutide pill on our platform, we've had constructive conversations with stakeholders across the industry," Hims & Hers said in a statement shared with Business Insider on Sunday. "As a result, we have decided to stop offering access to this treatment.""
"When Hims & Hers first made the compounded semaglutide pill available to customers on Thursday, the company said it met "rigorous clinical standards." "We adhere to all federal and state standards for compounding, and all active pharmaceutical ingredients (APIs) in compounded treatments are sourced exclusively from FDA-registered facilities," the company said. Compounding a new version of existing drugs typicallyoccurs when those drugs are facing a shortage, which has periodically been the case in recent years for some of the most popular weight-loss and diabetes drugs on the market. However, the Food and Drug Administration called out Hims & Hers in a statement issued the following day. The agency said it intends to restrict certain ingredients used in non-FDA-approved compounded drugs that are "mass-marketed by companies - including Hims & Hers and other compounding pharmacies - as similar alternatives to FDA-approved drugs.""
Hims & Hers introduced a once-a-day compounded semaglutide pill positioned as an option for needle-averse customers and those seeking smaller doses, resembling a lower-cost version of Wegovy. The company stated the product met rigorous clinical standards and that active pharmaceutical ingredients were sourced from FDA-registered facilities. About 48 hours after launch, Hims & Hers stopped offering the treatment following industry conversations. The Food and Drug Administration announced plans to restrict certain ingredients used in non‑FDA‑approved compounded drugs that are mass‑marketed as alternatives to approved GLP-1 therapies and specifically called out companies engaged in those practices.
Read at Business Insider
Unable to calculate read time
Collection
[
|
...
]